BUPHENYL
Drug
Horizon Pharma plc
Total Payments
$392,254
Transactions
8
Doctors
7
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $7.09 | 1 | 1 |
| 2023 | $43.54 | 2 | 2 |
| 2021 | $13.50 | 1 | 1 |
| 2017 | $392,190 | 4 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $388,929 | 1 | 99.2% |
| Consulting Fee | $3,250 | 2 | 0.8% |
| Food and Beverage | $75.17 | 5 | 0.0% |
Payments by Type
Research
$388,929
1 transactions
General
$3,325
7 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| COMPARATIVE, RANDOMIZED, SINGLE-DOSE, 3-WAY CROSSOVER BIOEQUIVALENCE STUDY OF BUPHENYL SODIUM PHENYLBUTYRATE 500 MG TABLETS AND TWO NEW FORMULATIONS FOLLOWING ORAL ADMINISTRATION IN HEALTHY ADULT SUBJECTS UNDER FASTING CONDITIONS | Horizon Pharma plc | $388,929 | 0 |
Top Doctors Receiving Payments for BUPHENYL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Lincoln, NE | $388,929 | 1 |
| , M.D | Medical Biochemical Genetics | San Diego, CA | $2,550 | 1 |
| , M.D | Pediatrics | San Francisco, CA | $700.00 | 1 |
| , MD | Family Medicine | Nevada, IA | $21.77 | 1 |
| , MD | Family Medicine | Nevada, IA | $21.77 | 1 |
| , D.P.M | Podiatrist | Chattanooga, TN | $13.50 | 1 |
| , M.D | Family Medicine | Phoenix, AZ | $11.04 | 1 |
| , M.D | Rheumatology | Buffalo, NY | $7.09 | 1 |
Ad
Manufacturing Companies
- Horizon Pharma plc $392,190
- Horizon Therapeutics plc $57.04
- Amgen Inc. $7.09
Product Information
- Type Drug
- Total Payments $392,254
- Total Doctors 7
- Transactions 8
About BUPHENYL
BUPHENYL is a drug associated with $392,254 in payments to 7 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is Horizon Pharma plc.
Payment data is available from 2017 to 2024. In 2024, $7.09 was paid across 1 transactions to 1 doctors.
The most common payment nature for BUPHENYL is "Unspecified" ($388,929, 99.2% of total).
BUPHENYL is associated with 1 research study, including "COMPARATIVE, RANDOMIZED, SINGLE-DOSE, 3-WAY CROSSOVER BIOEQUIVALENCE STUDY OF BUPHENYL SODIUM PHENYLBUTYRATE 500 MG TABLETS AND TWO NEW FORMULATIONS FOLLOWING ORAL ADMINISTRATION IN HEALTHY ADULT SUBJECTS UNDER FASTING CONDITIONS" ($388,929).